Abstract:Neurofibromatosis type 1 (NF1) syndrome is an autosomal dominant cancer predisposition syndrome defined by germline deletion of one NF1 allele. Somatic loss of heterozygosity in the remaining NF1 allele in Schwann lineage cells gives rise to benign tumors known as plexiform neurofibromas. These tumors have a high risk of transforming into malignant peripheral nerve sheath tumors (MPNST) through the sequential deletion of CDKN2A/B followed by recurrent mutations in SUZ12 or EED, constituting the inactivation of polycomb repressor complex 2 (PRC2). PRC2 is a transcriptional repressor complex involved in the silencing of several development and differentiation genes. Loss of this complex leads to a depletion in trimethylation marks on Histone H3 Lysine 27 (H3K27me3) and the subsequent gain of acetylation marks on the same lysine residue (H3K27Ac). These molecular hallmarks are shared with diffuse intrinsic pontine gliomas (DIPG) harboring the H3K27M mutation which prevents effective deposition of H3K27me3, thus having similar molecular phenotypes to MPNST. However, the full range of epigenetic consequences of these events are currently not well characterized. Additionally, given that MPNSTs originate from cells of neural crest origin and DIPGs from cells of neural origin, it is not know to what degree epigenetic changes stemming from H3K27me3-loss are general across tumors or are context-dependent based on cell-of-origin. In order to contribute to this effort, the Largaespada lab has engineered Schwann cell lines to harbor deletions in NF1 and either SUZ12 or EED and assayed the H3K27ac landscape of these cells in addition to patient-derived MPNST cell lines. Utilizing the ranked ordering of super enhancers (ROSE) algorithm, we have identified common super enhancers within each MPNST cell line. These super enhancer elements are located nearby a variety of putative oncogenes responsible for the maintenance of cell identity. These elements were then compared to publicly available data from DIPG primary and patient-derived samples to understand common regulatory events driven by loss of H3K27me3 as well as molecular signatures present only in MPNST or in DIPG that may be a result of PRC2 or H3K27M alone. We further characterized these super enhancers by assessing the expression levels of their associated genes to understand their role in transcriptional activation. These efforts provide a roadmap of the super enhancer landscape of both MPNSTs and DIPGs to investigate novel mechanisms of H3K27me3-dependent tumorigenesis while also contributing to knowledge of potential effects of H3K27me3-loss that dependent on the cell-of-origin for each respective tumor. Citation Format: Christopher M. Stehn, Minu Bhunia, Kyle Williams, Alex T. Larsson, Ariel Caride, Jeong-Heon Lee, Tamas Ordog, David Largaespada. Characterizing the super enhancer landscape of H3K27me3 loss in MPNST and DIPG [abstract]. In: Proceedings of the AACR Special Conference on Brain Cancer; 2023 Oct 19-22; Minneapolis, Minnesota. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_1) nr B009.

Epigenetic inactivation of DLC-1 in supratentorial primitive neuroectodermal tumor

Genetic Alterations of DLC1 in Medulloblastoma and Primitive Neuroectodermal Tumor

Genetic and Epigenetic Alterations of DLC-1, a Candidate Tumor Suppressor Gene, in Nasopharyngeal Carcinoma.

Promoter Hypermethylation Profile of RASSF1A, FHIT, and Sfrp1 in Intracranial Primitive Neuroectodermal Tumors.

[Different Hypermethylation Status of RASSF1A in Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor].

Identification of A Minimal Region of Genetic Loss at 8p23.1 and Investigation of Gata4 As A Candidate Tumor Suppressor Gene in Medulloblastoma

Hypermethylation of TIG1 Promoter in Intracranial Primitive Neuroectodermal Tumors

Aberrant methylation of the 8p22 tumor suppressor gene DLC1 in renal cell carcinoma.

Identification of DLC-1 Expression and Methylation Status in Patients with Non-Small-cell Lung Cancer

Epigenetic Silencing of the 3p22 Tumor Suppressor DLEC1 by Promoter CpG Methylation in Non-Hodgkin and Hodgkin Lymphomas

Tumor-Specific Methylation of the 8p22 Tumor Suppressor Gene DLC1 is an Epigenetic Biomarker for Hodgkin, Nasal NK/T-Cell and Other Types of Lymphomas

Ten-eleven translocation protein 1 modulates medulloblastoma progression

Aberrant Methylation and Deacetylation of Deleted in Liver Cancer-1 Gene in Prostate Cancer: Potential Clinical Applications.

Identification of Aberrant Methylation of DLC-1 by Pyrosequencing in Acute Lymphoblastic Leukemia in Children

Molecular analysis of PinX1 in medulloblastomas.

Promoter Hypermethylation along with LOH, but Not Mutation, Contributes to Inactivation of DLC-1 in Nasopharyngeal Carcinoma.

PDTB-08. Mir-449a, A POTENTIAL DIAGNOSTIC BIOMARKER FOR WNT GROUP OF MEDULLOBLASTOMA

NeuroD1 Dictates Tumor Cell Differentiation in Medulloblastoma.

Malignant Transformation of a Dysembryoplastic Neuroepithelial Tumor (DNET) Characterized by Genome-Wide Methylation Analysis

Epigenetic regulation of wnt pathway antagonists in human glioblastoma multiforme

Abstract B009: Characterizing the super enhancer landscape of H3K27me3 loss in MPNST and DIPG